Avalo Therapeutics, Inc. (AVTX) intrinsic value & 10-year financials
Avalo Therapeutics, Inc. (AVTX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue shrank 28.1% a year to $59.0K, with an average return on invested capital of -16857.2%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $11.27
- Market cap
- $151.1M
- Revenue (FY2025)
- $59.0K
- Revenue growth (10-yr CAGR)
- -28.1%
- ROIC (10-yr avg)
- -16857.2%
- Free cash flow (FY2025)
- —
AVTX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $59.0K | -$78.3M | -$5.84 | — | -123601.7% | -220.8% |
| FY2024 | $441.0K | -$35.1M | -$20.91 | — | -15535.6% | -150575.8% |
| FY2023 | $1.9M | -$31.5M | -$4.22 | — | -1421.6% | 3208.3% |
| FY2022 | $18.1M | -$41.7M | -$0.16 | -$26.8M | -207.4% | -19299.0% |
| FY2021 | $5.4M | -$84.4M | — | -$71.0M | -1521.6% | -1634.3% |
| FY2020 | $6.7M | -$63.5M | — | -$40.6M | -1087.4% | -554.2% |
| FY2019 | $6.8M | -$16.1M | — | -$19.4M | -239.1% | -73.1% |
| FY2018 | $18.3M | -$40.1M | -$0.04 | -$3.7M | -214.5% | -154.0% |
| FY2017 | $27.8M | $11.9M | $0.02 | $12.5M | 49.9% | 104.4% |
| FY2016 | $1.2M | -$16.5M | -$0.07 | -$14.6M | -1394.6% | 626.3% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Avalo Therapeutics, Inc. is facing top-line stagnation, with revenue contracting over the decade.
Avalo Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -165.5% ROIC.
Over the decade, Avalo Therapeutics, Inc. shows that management has aggressively returned capital to shareholders by retiring 94.4% of outstanding shares.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Avalo Therapeutics, Inc. is modeled at -28.1% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-0.64 per share.